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A B S T R A C T
A main cause of treatment failure for AML patients is resistance to chemotherapy. Survival of
AML cells may depend on mechanisms that elude conventional drugs action and/or on the
presence of leukemia initiating cells at diagnosis, and their persistence after therapy. MDR1 gene
is an ATP-dependent drug efflux pump known to be a risk factor for the emergence of resistance,
when combined to unstable cytogenetic profile of AML patients.
In the present study, we analyzed the sensitivity to conventional chemotherapeutic drugs of 26
samples of primary blasts collected from AML patients at diagnosis. Detection of cell viability and
apoptosis allowed to identify two group of samples, one resistant and one sensitive to in vitro
treatment. The cells were then analyzed for the presence and the activity of P-glycoprotein. A
comparative analysis showed that resistant samples exhibited a high level of MDR1 mRNA as well
as of P-glycoprotein content and activity. Moreover, they also displayed high PI3K signaling.
Therefore, we checked whether the association with signaling inhibitors might resensitize re-
sistant samples to chemo-drugs. The combination showed a very potent cytotoxic effect, possibly
through down modulation of MDR1, which was maintained also when primary blasts were co-
cultured with human stromal cells. Remarkably, dual PI3K/mTOR inactivation was cytotoxic also
to leukemia initiating cells. All together, our findings indicate that signaling activation profiling
associated to gene expression can be very useful to stratify patients and improve therapy.
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1. Introduction
Acute myeloid leukemia (AML) is a progressive myeloid neoplasm associated with maturation arrest and accumulation of
myeloblasts in peripheral blood and bone marrow (Döhner et al., 2015; Mohammadiasl et al., 2016). Although approximately 35% of
AML patients are currently treated, disease relapse and drug resistance are still big challenges (Saultz and Garzon, 2016), so that
10–40% of patients show primary resistance or early relapse, and it is commonly reckoned that chemotherapy alone will not
ameliorate the outcome in the future. Primary therapy resistance implies failure to achieve complete remission (Thol et al., 2015).
Efflux of drug through the ATP-binding cassette transporters (ABC) such as the P-glycoprotein (P-gp) encoded by the multidrug
resistance gene1 (MDR1) is one of the most important mechanisms of resistance in AML (Broxterman et al., 2000). MDR expression
increases with age, being P-gp expressed in 47% of elderly AML cases and in 34% of younger patients. Although its expression as a
prognostic value for survival is still a matter of debate, it is well-known that high P-gp expression at diagnosis, combined with
unstable cytogenetic profiles or epigenetic mutations in hematopoietic progenitors, correlates with poor prognosis due to resistance
(van der Heuvel-Eibrink et al., 2001). However, hitherto several efforts to block P-gp/ABC transporter by the use of inhibitors failed
due to dose-limiting toxicities and off-target effects (Mahadevan and List, 2004).
Mutated progenitor cells, the so-called leukemic initiating cells (LICs), which constitute a subpopulation able to live in very harsh
conditions such as hypoxic environment (Leibovitch and Topisirovic, 2018) in a quiescence phase similar to hematopoietic stem cells
(HSCs) (Ratti et al., 2018), are another source of resistance to chemotherapy and disease relapse (Vergez et al., 2011). This sub-
population is more therapy-resistant than other cell populations (Terwijn et al., 2014) and several studies showed that in particular
the CD34+/CD38- compartment is very important in clinical setting, because of mutations described with low frequency at diagnosis,
which are found highly represented at relapse (Griessinger et al., 2016). These mutations are possibly connected with the aberrant
activation of the PI3K/AKT/mTOR pathway that has been identified as a feature of LICs in acute leukemia (Kharas et al., 2010; Follo
et al., 2013; Martelli et al., 2014; McCubrey and Cocco, 2014). PI3K/AKT/mTOR signaling controls proliferation, differentiation and
survival of hematopoietic cells (Martelli et al., 2010; Ricciardi et al., 2017; Hermida et al., 2017). Under normal conditions, PI3K
activation is triggered through extracellular binding of ligands, which in turn induce the activation of corresponding receptor tyrosine
kinases (Ruzzene et al., 2017; Payrastre and Cocco, 2015; Yang et al., 2013). PI3K activation leads to the conversion of phospha-
tidylinositol-4, 5-bisphosphate (PIP2) to phosphatidylinositol-3, 4, 5-trisphosphate (PIP3), which in turn recruits AKT and phos-
phoinositide-dependent kinase 1 (PDK1) to the plasma membrane resulting in AKT phosphorylation byPDK1 at Thr308. For full
activation, AKT is also phosphorylated by mTORC2 at Ser473 (Ruzzene et al., 2017; Toker and Marmiroli, 2014). PI3K signaling is
negatively modulated by dephosphorylation of PIP3 by the lipid phosphatases PTEN and SHP1/2 (Ciuffreda et al., 2014). Because
several key elements of this pathway have been found mutated in cancer, much emphasis has been placed on developing drugs which
target PI3K signaling (Fransecky et al., 2015; Fragoso and Barata, 2017; Ruvolo, 2017; Park et al., 2010), leading to a number of
molecules being trialled in several malignancies, including AML. While it is well established that over 60% of AML patients show
increased activity of PI3K/AKT signaling (Park et al., 2010; Bertacchini et al., 2014, 2015), its relationship with resistance to therapy
is not completely settled (Abrams et al., 2017; Marmiroli et al., 2015). Previous studies by us and others showed that aberrant
signaling by the abovementioned pathway modulates expression of the MDR1 gene in acute leukemia (Tazzari et al., 2007; Seo et al.,
2010). We report here that in primary cells collected at diagnosis from AML patients, characterized by detectable MDR1 expression,
combined treatment with signaling inhibitors and conventional chemotherapy results in a strong cytotoxic effect, able to kill also
leukemia initiating cells. These results once again point out the importance of extensive patient profiling for signaling activation,
MDR1 expression and LICs to identify specific subgroups of patients and select the best therapeutic protocols.
2. Materials and methods
Cell culture-DMSO-stored primary blast cells samples, previously collected from patients with newly diagnosed AML, were ob-
tained from bone marrow or peripheral blood (Bertacchini et al., 2014). Mononuclear cells were isolated using the Ficoll–Hypaque
system. Only samples with Trypan blue-positive cells< 20% and blast count> 70% were used in this study. The human leukemic
cell lines HL60 and CEM, and the human stromal cell line HS-5 were purchased from ATCC (American Type Culture Collection,
Manassas, VA, USA), the cell sublines HL60-R and CEM-R were a generous gift of Dr. Cianfriglia and were obtained as described. Both
primary AML cells and leukemia cell lines were cultured in RPMI 1640 with 10% FBS while HS-5 cell line was cultured in DMEM with
10% FBS, at 37 °C in humidified atmosphere with 5% CO2. Cells were treated with Etoposide 10mM, Cytarabine 1mM, PF-
04691502 500 nM and NVP-BEZ235 as indicated in the figures. Viability of AML cells treated with inhibitors was determined by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay as previously described (Mediani
et al., 2015).
Protein extraction, immunoblotting and RPPA-Cells were extracted by addition of Lysis buffer (20mM Tris-Cl, pH 7.0, 1% NP-40,
150mM NaCl, 10% glycerol, 10mM EDTA, 20mM NaF, 5mM sodium pyrophosphate, 1 mM Na3VO4, and freshly added Sigma-
Aldrich Protease Inhibitor Cocktail) at 4 °C for 10min as described previously (Maraldi et al., 1993). Lysates were cleared by cen-
trifugation and used for immunoprecipitation experiments, as described (Lucarelli et al., 2002). In brief, total lysates were boiled in
SDS sample buffer, resolved by SDS-PAGE, then immunoblotted on Immobilon-P membranes (Millipore, MA), probed by Western
blotting with the indicated antibodies, and detected by the Supersignal substrate chemiluminescence detection kit (Euroclone, Milan,
IT) on a Kodak Image Station 440CF with the Kodak 1D Image software.
For RPPA analysis, array assembly, printing, staining and analysis were performed as reported previously (Maraldi et al., 2011;
Bertacchini et al., 2014; Serafin et al., 2017). Briefly, cells were lysed on ice for 20 min in TPER Reagent (Pierce, Rockford, IL),
J. Bertacchini et al. Advances in Biological Regulation 68 (2018) 2–9
3
300 mM NaCl, 1 mM Na Orthovanadate, 200 mM PEFABLOC (AEBSF) (Roche, Basel, Switzerland). All samples were diluted to a final
concentration of 0.5 mg/ml with Tris-Glycine SDS buffer + β-mercaptoethanol and then 30 μl of each sample were loaded on a 383-
well plate in a series of 4-fold dilutions and printed in duplicate on nitrocellulose coated glass slides (FAST Slides, Whatman). Then,
the slides were subjected to immunostaining with the indicated antibodies. Slides were stained on an automated slide stainer (Dako,
Carpinteria, CA, U.S.A) using a biotin-linked peroxidase catalyzed signal amplification.
For detection of apoptosis, 1× 106 cells were washed twice with PBS and stained with Annexin V–FITC and Propidium Iodide (PI)
in 1X binding buffer (10mM HEPES pH 7.4, 140mM NaOH, 2.5 mM CaCl2) for 15 min at room temperature in the dark. Both early
apoptotic (Annexin V+, PI-) and late (Annexin V+ and PI+) apoptotic cells were included in cell death determinations. Annexin V
negative + PI-negative cells represent viable cells. The analysis was performed on a FACSCalibur (BD Biosciences, NJ, USA).
For detection of rhodamine 123 efflux, cells were centrifuged and the pellet was re-suspended in cold loading buffer containing
rhodamine 123, in absence or presence of 50 μM verapamil, and incubated on ice. Cells were washed twice and kept at different
temperatures for 15min. Then, test tubes were put on ice to stop the reaction, and analyzed by flow cytometry.
RT-PCR-Total RNA was extracted with the RNeasy Mini Kit (Qiagen, Valencia, CA), according to manufacturer's instructions. The
concentration of total RNA was determined by measuring the absorbance both at 260 nm (A260) and at 280 nm (A280) in a Nanodrop
spectrophotometer. Quantification of gene expression was performed through Real Time quantitative PCR in duplicates with
MaximaTM SYBR® Green qPCR Master Mix 2X (Fermentas, St. Leon-Rot, Germany) with detection on an Applied Biosystem 7500 RT-
PCR System (Applied Biosystems). Primers for MDR1 were as follows: F: 5′-CGAGATCCCTCCAAAATCAA-3′, R: 5′-TTCACACCCAT
GACGAACAT-3′ Relative gene expression quantification was based on the comparative threshold cycle method (2–ΔΔCt, Cycle-
threshold, Ct) with normalization of the raw data to the included housekeeping gene (GAPDH, glyceraldehyde 3-phosphate dehy-
drogenase).
3. Results and discussion
3.1. Primary AML blast cells display differential sensitivity to chemotherapeutic agents
Twenty-six samples of primary cells from AML patients, collected at diagnosis, were cultured for 24 h after addition to the
medium of the conventional chemo agents Etoposide + Cytarabine. Ten peripheral blood samples from healthy donors were used as
controls. Cell viability was analyzed by MTT assay. As expected, the drugs were unable to kill cells in 65% of AML samples (n = 17)
(Fig. 1a). Cells from the remaining samples underwent extensive apoptosis, as well as from healthy donors, as demonstrated by the
presence of cleaved Caspase 3 and 7 (Fig. 1b). To identify at which level cellular resistance might occur, we first determined the
expression of the multidrug resistance gene, MDR1, in all samples (n= 26) by RT-PCR. Parental HL60 cells and its doxorubicin-
Fig. 1. MTT analysis of cell viability. a) Cell viability, expressed as % of positively stained cells following addition of Etoposide 10 mM + Cytarabine 1 mM for 24 h
was assessed by MTT assay of triplicate cultures. Data represent mean ± SD viability of three independent experiments. b) Cleaved fragments of Caspase 3 and
Caspase 7 were revealed by Western blotting. Actin was probed to monitor protein loading. The lower part reports the % of cells positive to Annexin V staining from
the same samples.
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resistant subline, from here on called respectively HL60-S and HL60-R, were used as negative and positive controls. Samples with at
least two fold MDR1 mRNA content compared to that of HL60S cells, which were set as 1, were regarded as MDR1-positive. We found
that 11 samples (42%) did not express MDR1. All other samples were classified as MDR1-positive, although 9 samples (35%) showed
a very high expression of MDR1 mRNA whereas the remaining samples had much lower levels (Fig. 2a). Next, P-gp protein level was
assessed by FACS, showing a complete overlapping between protein and mRNA levels (Fig. 2b). Furthermore, comparing the results
from cell viability and the relative expression of MDR1 it is clear that almost all of the 17 samples that were resistant to chemotherapy
express MDR1, although to different degrees, as 9 of them display high level and 6 showed low level. Moreover, 2 samples did not
express it.
MDR1-positive AML cells are resensitized to chemotherapy through dual inhibition of PI3K/mTOR signaling.
Previous studies by us and others demonstrated that primary cells from AML patients with a hyper-activation of signaling
pathways are less sensitive to conventional drugs (Wee et al., 2009; Su et al., 2018), therefore we asked whether the low sensitivity of
some AML samples to Etoposide + Cytarabine is associated also to a specific phosphoprofile, besides to MDR1 expression. Thus, by
the use of RPPA, we analyzed proteins and phosphoproteins belonging to some signaling pathways involved in most cellular func-
tions. Our findings confirm that the PI3K/AKT/mTOR pathway displayed higher signaling in resistant samples (Fig. 3). Since it has
been claimed that in T-ALL cell lines AKT is able to downregulate the expression and the activity of MDR1 (Chiarini et al., 2010; Seo
et al., 2010), we investigated the effect of blocking this signaling cascade in the resistant subgroup. Therefore samples were cultured
for 24 h in presence or not of a drug cocktail where Etoposide + Cytarabine were combined to the dual PI3K/mTOR inhibitors PF-
04691502 or NVPBEZ235 (Mediani et al., 2015). FACS analysis demonstrated that this combination strongly enhanced the cyto-
toxicity induced by the chemotherapeutic drugs alone (Fig. 4). Furthermore, we analyzed the expression of MDR1 in 6 resistant
primary AML samples, as well as in the HL60-R and CEM-R leukemia cell lines, treated or not with either PF-04691502 or
NVPBEZ235. RT-PCR analysis showed that MDR1 expression was downregulated following addition of either of the two inhibitors for
Fig. 2. Expression of MDR1 in AML patients at diagnosis. a) MDR1 expression of primary blast samples from AML patients was analyzed by RT-PCR. MDR1 mRNA
content in the parental cell lines HL60-S was set as 1, and used as a threshold to assess the relative expression in AML samples. Error bars represent ST DEV. b) For
detection of P-gp protein content, cells were washed with PBS and incubated for 1 h at 4 °C with 4 μL/106 cells of a FITC-conjugated monoclonal anti-P-gp to an
extracellular epitope. Then, samples were washed with PBS and analyzed by flow cytometry. HL60-R cells were analyzed as positive control. Representative AML
samples with different amount of P-gp expression are shown.
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24 h, indicating that the abovementioned molecules boosted the ability of conventional drugs to kill leukemic blasts through MDR1
downregulation (Fig. 5a). This result is in complete agreement with what previously shown in a model of T-ALL (Chiarini et al.,
2010). Besides, a similar mechanism has been observed following treatment with the AKT inhibitor perifosine in patients with breast
cancer (Lin et al., 2012), with the PI3K inhibitor LY294002 in gastric tumor (Xie et al., 2013), and with the dual inhibitor of PI3K/
mTOR, PI103, in sarcoma cell lines (Marklein et al., 2012), confirming the role of the above pathway in the transcriptional regulation
of the drug transporter.
To ascertain whether not only MDR1 expression but also P-gp activity is modified by the above drugs, we analyzed the uptake of
the fluorescent dye, and MDR1 substrate, rhodamine 123 by primary cells treated or not with the dual PI3K/mTOR inhibitors, or with
Verapamil as a positive control. Indeed, we found that P-gp-mediated efflux of rhodamine 123 was significantly reduced after PI3K/
mTOR inhibition for 24 h (Fig. 5b). Having shown that inhibition of PI3K downstream signaling can restore responsiveness to
Etoposide + Cytarabine, possibly through down-modulation of MDR1 expression and activity, next we asked whether the cytotoxic
action of the above drug association would be preserved also in vivo. To partially mimic the protective bone marrow micro-
environment, the above samples were co-cultured with human stromal cells HS-5 for 72 h before treatment. The apoptotic population
was assessed by FACS using anti-CD33/Annexin V staining. Interestingly, while cell co-culturing counteracts apoptosis induced by
Etoposide + Cytarabine in all samples tested, inhibition of PI3K/mTOR, particularly by PF-04691502, overcomes the pro-survival
effect of HS-5 cells and shows towards leukemic blasts the same cytotoxicity detected in the absence of HS-5 co-cultures. (Fig. 6a and
b). These findings suggested that in AML patients resistant to conventional chemotherapy and characterized by a high PI3K signaling
phenotype, addition of inhibitors of the PI3K pathway to the therapy should be taken into consideration.
Fig. 3. RPPA analysis of signaling pathway activation in primary AML cells. Heatmap representation of the RPPA analysis of primary cells from AML patients subjected
to immunostaining with antibodies to the indicated signaling molecules. The color in each cell reflects the level of expression. (For interpretation of the references to
color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Evaluation of apoptosis induced by association of conventional drugs to PI3K/mTOR inhibitors. Cells were treated with Etoposide 10 mM+ Cytarabine 1 mM,
alone or combined to either PF-04691502 500 nM or NVPBEZ235 500 nM, for 24 h. Then apoptosis was assessed by Annexin V staining and flow cytometry.
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3.2. LICs are sensitive to PI3K/mTOR modulation
LICs originate from HSCs differentiation and give rise to all leukemic cells (Dick, 1997; Vergez et al., 2011). These cells are
generally in quiescence phase and are thought to be critical to the growth of AML and emergence of resistance to chemotherapy
(Terwijn et al., 2014; Griessinger et al., 2016). Remarkably, ectopic activation of PI3K/AKT/mTOR signaling is a distinctive trait of
LICs (Kharas et al., 2010). In particular, Chiarini and coworkers evaluated the effect of NVPBEZ235 on T-ALL, showing that this drug
targets LICs and that its association with conventional chemotherapy is highly synergistic (Chiarini et al., 2010). Moreover, other
groups recently demonstrated the role of PI3K inhibitors in the elimination of LICs in T-ALL patients (Schubbert et al., 2014;
Blackburn et al., 2014). On these basis, we asked whether a similar effect can be triggered in AML. Thus, all samples from the high
PI3K signaling group were analyzed. To distinguish LICs from HSCs, in this study only CD34+/CD38-/CD123+ cells were considered.
Fig. 5. PI3K/mTOR inhibition down-regulates MDR1 expression and activity. a) Six samples of primary AML cells (P21-P26) were treated with PF-04691502 500 nM
or NVPBEZ235 500 nM for 24 h prior to RNA extraction and MDR1 quantification. The MDR1-resistant HL60-R and CEM-R cells were analyzed as positive controls.
Data are expressed as arbitrary units and are the means ± SEM of three independent assays. b) Cells were exposed to 5.25 μM rhodamine 123 for 30min at 37 °C in the
absence or presence of either verapamil 50 μM, PF-04691502 500 nM or NVPBEZ235 500 nM. After washing, rhodamine 123 accumulation was quantified by flow
cytometry.
Fig. 6. Four representative AML primary samples were cultured for 72 h with or without the human stromal cell line HS-5 followed by addition of Etoposide
10 mM + Cytarabine 1 mM and PF-04691502 (500 nM) (panel a) or NVPBEZ235 (500 nM) (panel b) for 24 h. At the end of treatment, cells were detached and
analyzed by flow cytometry for the expression of blast cells specific marker CD33 and Annexin V staining.
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In agreement with previous reports, we found a percentage of CD34+/CD38-/CD123 + cells ranging from 0.2% to 15% calculated
on the total cell number, depending on the patient. Next, eight such samples were treated with NVPBEZ235 or PF-04691502 and cell
viability was analyzed by PI and Annexin V labelling and flow cytometry. We found that 4 out of the 8 samples tested were highly
sensitive to addition of both NVPBEZ235 and PF-04691502, with up to 80% LICs killed after 24 h treatment in sample P20 and P21
(Fig. 7). This indicates that PI3K and downstream signaling have a fundamental role in survival of LICs, and must be regarded
therefore as a point of weakness, to be targeted in this AML cell subpopulation.
In conclusion, here not only we demonstrated that the above key signaling cascade controls the expression of P-gp and favors the
survival of LICs in more than 30% of the AML primary samples tested, but our results also indicate that signaling inhibition can
overcome drug resistance reducing MDR1 expression, as well as eliminating LICs in 50% of the tested samples. On these basis, it is
tempting to speculate that addition of PI3K/mTOR inhibitors, in the nM range, to conventional chemotherapy might decrease the risk
of disease relapse. Therefore we reckon that profiling signaling pathways, besides P-gp, might be a powerful tool to predict patients
who will not be responsive to conventional AML therapy but may be responsive to alternative therapies.
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